Legend Biotech Quick Ratio (LEGN) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Legend Biotech Corporation  (NASDAQ: LEGN)

Legend Biotech's Quick Ratio

LEGN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 1.42 below Legend Biotech Corporation average.

Within Major Pharmaceutical Preparations industry 200 other companies have achieved higher Quick Ratio than Legend Biotech in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 0 to 973.

Explain Quick Ratio?
How much Cash & cash equivalents LEGN´s has?
What are LEGN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LEGN Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 97.7 % -40.84 % 7.95 % 8.88 % 11.57 %
Y / Y Cash & cash equivalent Change 214.58 % -39.28 % 32.46 % -50.79 % -77.56 %
Quick Ratio MRQ 1.42 1.53 0.83 1.38 0.89
LEGN's Total Ranking # 973 # 0 # # #
Seq. Current Liabilities Change 249.6 % -43.43 % 0.64 % -0.67 % 4.62 %
Seq. Cash & cash equivalent Change 223.39 % 4.62 % -39.65 % 54.06 % -37.58 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 201
Healthcare Sector # 370
Overall Market # 973


Quick Ratio Statistics
High Average Low
4.43 2.4 0.89
(Dec 31 2023)   (Dec 31 2024)




Financial Statements
Legend Biotech's Current Liabilities $ 636 Millions Visit LEGN's Balance sheet
Legend Biotech's Cash & cash equivalent $ 902 Millions Visit LEGN's Balance sheet
Source of LEGN's Sales Visit LEGN's Sales by Geography


Cumulative Legend Biotech's Quick Ratio

LEGN's Quick Ratio for the trailling 12 Months

LEGN Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 19.54 % -3.58 % 9.01 % 8.58 % 6.79 %
Y / Y Cash & cash equivalent TTM Growth 2.4 % -55.08 % -56.46 % -68.23 % -55.38 %
Quick Ratio TTM 1.29 1.11 1.14 1.11 1.51
Total Ranking TTM # 2363 # 0 # # #
Seq. Current Liabilities TTM Growth 27.46 % -9.88 % 1.9 % 2.14 % 2.81 %
Seq. Cash & cash equivalent TTM Growth 48.29 % -12.4 % 4.7 % -24.71 % -34.95 %

Quick ratio ranking by company, industry and sector >> Back to LEGN Financial Strength Comparisons >> Go to Compare LEGN Quick Ratio to its Competitors

On the trailing twelve months basis LEGN Cash & cash equivalent more than doubled by 214.58 % in Q4 2025 year on year, faster than Current Liabilities, this led to increase in in Legend Biotech's Quick Ratio to 1.29, Quick Ratio remained below LEGN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 280 other companies have achieved higher Quick Ratio than Legend Biotech. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 2363.

Explain Quick Ratio?
How much Cash & cash equivalents LEGN´s has?
What are LEGN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 281
Healthcare Sector # 588
Within the Market # 2363


trailing twelve months Quick Ratio Statistics
High Average Low
4.43 3.1 2.46
(Dec 31 2023)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Enanta Pharmaceuticals Inc  3.89 $ 188.864  Millions$ 48.555  Millions
Lixte Biotechnology Holdings Inc   3.83 $ 5.107  Millions$ 1.333  Millions
Cocrystal Pharma Inc   3.74 $ 7.025  Millions$ 1.876  Millions
Entrada Therapeutics Inc   3.70 $ 90.394  Millions$ 24.451  Millions
Rani Therapeutics Holdings Inc   3.66 $ 49.709  Millions$ 13.566  Millions
Tempest Therapeutics Inc   3.63 $ 7.707  Millions$ 2.122  Millions
Seaport Therapeutics Inc   3.62 $ 46.242  Millions$ 12.782  Millions
Genprex Inc   3.60 $ 7.831  Millions$ 2.175  Millions
Cyclerion Therapeutics Inc   3.60 $ 3.240  Millions$ 0.900  Millions
Forte Biosciences Inc   3.60 $ 76.957  Millions$ 21.383  Millions
Cadrenal Therapeutics Inc  3.60 $ 5.710  Millions$ 1.588  Millions
Renovorx Inc   3.58 $ 7.024  Millions$ 1.962  Millions
Arrowhead Pharmaceuticals Inc   3.54 $ 692.818  Millions$ 195.487  Millions
Syndax Pharmaceuticals Inc   3.44 $ 413.686  Millions$ 120.116  Millions
Alumis inc   3.38 $ 308.501  Millions$ 91.143  Millions
Quoin Pharmaceuticals Ltd   3.38 $ 18.745  Millions$ 5.547  Millions
Rhythm Pharmaceuticals Inc   3.38 $ 388.949  Millions$ 115.197  Millions
Urogen Pharma Ltd   3.32 $ 160.074  Millions$ 48.225  Millions
Decoy Therapeutics Inc   3.29 $ 13.710  Millions$ 4.166  Millions
Bolt Biotherapeutics Inc   3.26 $ 27.505  Millions$ 8.435  Millions
Bullfrog Ai Holdings Inc   3.25 $ 2.184  Millions$ 0.672  Millions
Madrigal Pharmaceuticals Inc   3.18 $ 983.559  Millions$ 309.270  Millions
Aclaris Therapeutics Inc   3.17 $ 90.751  Millions$ 28.645  Millions
Pyxis Oncology Inc   3.16 $ 66.857  Millions$ 21.131  Millions
Skye Bioscience Inc   3.14 $ 25.737  Millions$ 8.206  Millions
Acurx Pharmaceuticals inc   3.12 $ 7.556  Millions$ 2.421  Millions
Gri Bio Inc   3.11 $ 8.229  Millions$ 2.643  Millions
Cypherpunk Technologies Inc   3.11 $ 14.035  Millions$ 4.520  Millions
Inhibitor Therapeutics Inc   3.10 $ 2.375  Millions$ 0.766  Millions
Kyntra Bio Inc   3.04 $ 88.978  Millions$ 29.242  Millions

Date modified: 2026-09-08T18:38:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.